The potential use of nintedanib in conditions that commonly occur with fibrotic lung conditions, such as systemic sclerosis are being investigated. Scleroderma News, 12/22/2015. (Also see Pulmonary Fibrosis Treatments and Clinical Trials)
This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.